Kinase-Centric Computational Drug Development

Klebl, 2011, Protein Kinases as Drug Targets, 10.1002/9783527633470 Wood, 2007, The Genomic Landscapes of Human Breast and Colorectal Cancers, Science, 318, 1108, 10.1126/science.1145720 Pray, 2008, Gleevec: The Breakthrough in Cancer Treatment, Nat. Educ., 1, 37 Manning, 2002, The Protein Kinase Complement of the Human Genome, Science, 298, 1912, 10.1126/science.1075762 Berman, 2000, The Protein Data Bank, Nucleic Acids Res., 28, 235, 10.1093/nar/28.1.235 Kooistra, 2016, KLIFS: A Structural Kinase-Ligand Interaction Database, Nucleic Acids Res., 44, D365, 10.1093/nar/gkv1082 Eid, 2017, KinMap: A Web-Based Tool for Interactive Navigation through Human Kinome Data, BMC Bioinformatics, 18, 16, 10.1186/s12859-016-1433-7 Stamos, 2002, Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex With a 4-Anilinoquinazoline Inhibitor, J. Biol. Chem., 277, 46265, 10.1074/jbc.M207135200 DeLano, 2002, Pymol: An Open-Source Molecular Graphics Tool, CCP4 Newsl. Protein Crystallogr., 700, 44 Fährrolfes, 2017, ProteinsPlus: A Web Portal for Structure Analysis of Macromolecules, Nucleic Acids Res., 45, 1, 10.1093/nar/gkx333 Volkamer, 2015, Pocketome of Human Kinases: Prioritizing the ATP Binding Sites of (Yet) Untapped Protein Kinases for Drug Discovery, J. Chem. Inf. Model., 55, 538, 10.1021/ci500624s Brooijmans, 2010, An Enriched Structural Kinase Database to Enable Kinome-Wide Structure-Based Analyses and Drug Discovery, Protein Sci., 19, 763, 10.1002/pro.355 Möbitz, 2015, The ABC of Protein Kinase Conformations, Biochim. Biophys. Acta, 1854, 1555, 10.1016/j.bbapap.2015.03.009 Roskoski, 2016, Classification of Small Molecule Protein Kinase Inhibitors Based Upon the Structures of Their Drug-Enzyme Complexes, Pharmacol. Res., 103, 26, 10.1016/j.phrs.2015.10.021 Wu, 2016, Small-Molecule Kinase Inhibitors: An Analysis of FDA-Approved Drugs, Drug Discov. Today, 21, 5, 10.1016/j.drudis.2015.07.008 Zhang, 2009, Targeting Cancer With Small Molecule Kinase Inhibitors, Nat. Rev. Cancer, 9, 28, 10.1038/nrc2559 Fang, 2013, Strategies for the Selective Regulation of Kinases With Allosteric Modulators: Exploiting Exclusive Structural Features, ACS Chem. Biol., 8, 58, 10.1021/cb300663j Okamoto, 2015, Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization, ACS Med. Chem. Lett., 6, 89, 10.1021/ml500394m Zhao, 2017, Determining Cysteines Available for Covalent Inhibition Across the Human Kinome, J. Med. Chem., 60, 2879, 10.1021/acs.jmedchem.6b01815 Karaman, 2008, A Quantitative Analysis of Kinase Inhibitor Selectivity, Nat. Biotechnol., 26, 127, 10.1038/nbt1358 Law, 2014, DrugBank 4.0: Shedding New Light on Drug Metabolism, Nucleic Acids Res., 42, D1091, 10.1093/nar/gkt1068 Bento, 2014, The ChEMBL Bioactivity Database: An Update, Nucleic Acids Res., 42, D1083, 10.1093/nar/gkt1031 Morphy, 2010, Selectively Nonselective Kinase Inhibition: Striking the Right Balance, J. Med. Chem., 53, 1413, 10.1021/jm901132v Bamborough, 2012, System-Based Drug Discovery Within the Human Kinome, Expert Opin. Drug Discov., 7, 1053, 10.1517/17460441.2012.724056 Scapin, 2006, Protein Kinase Inhibition: Different Approaches to Selective Inhibitor Design, Curr. Drug Targets, 7, 1443, 10.2174/1389450110607011443 Azzaoui, 2007, Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data, ChemMedChem, 2, 874, 10.1002/cmdc.200700036 Uitdehaag, 2012, A Guide to Picking the Most Selective Kinase Inhibitor Tool Compounds for Pharmacological Validation of Drug Targets, Br. J. Pharmacol., 166, 858, 10.1111/j.1476-5381.2012.01859.x Arrowsmith, 2015, The Promise and Peril of Chemical Probes, Nat. Chem. Biol., 11, 536, 10.1038/nchembio.1867 Zhang, 2012, Targeting the Human Kinome for Cancer Therapy: Current Perspectives, Crit. Rev. Oncog., 17, 233, 10.1615/CritRevOncog.v17.i2.70 Fedorov, 2010, The (Un)targeted Cancer Kinome, Nat. Chem. Biol., 6, 166, 10.1038/nchembio.297 Greenman, 2007, Patterns of Somatic Mutation in Human Cancer Genomes, Nature, 446, 153, 10.1038/nature05610 Fleuren, 2016, The Kinome “at Large” in Cancer, Nat. Rev. Cancer, 16, 83, 10.1038/nrc.2015.18 Patel, 2012, Objective Assessment of Cancer Genes for Drug Discovery, Nat. Rev. Drug Discov., 12, 35, 10.1038/nrd3913 Manning, 2009, Challenges and Opportunities in Defining the Essential Cancer Kinome, Sci. Signal., 2, pe15, 10.1126/scisignal.263pe15 Workman, 2013, Drugging Cancer Genomes, Nat. Rev. Drug Discov., 12, 889, 10.1038/nrd4184 Holohan, 2013, Cancer Drug Resistance: An Evolving Paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599 Mok, 2017, Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer, N. Engl. J. Med., 376, 629, 10.1056/NEJMoa1612674 Forbes, 2009, COSMIC (the Catalogue of Somatic Mutations In Cancer): A Resource to Investigate Acquired Mutations in Human Cancer, Nucleic Acids Res., 38, D652 Tang, 2008, Dual MET-EGFR Combinatorial Inhibition Against T790M-EGFR-Mediated Erlotinib-Resistant Lung Cancer, Br. J. Cancer, 99, 911, 10.1038/sj.bjc.6604559 Mendoza, 2011, The Ras-ERK and PI3K-mTOR Pathways: Cross-Talk and Compensation, Trends Biochem. Sci., 36, 320, 10.1016/j.tibs.2011.03.006 Vidović, 2014, Large-Scale Integration of Small Molecule-Induced Genome-Wide Transcriptional Responses, Kinome-Wide Binding Affinities and Cell-Growth Inhibition Profiles Reveal Global Trends Characterizing Systems-Level Drug Action, Front. Genet., 5, 342 Fedorov, 2007, A Systematic Interaction Map of Validated Kinase Inhibitors With Ser/Thr Kinases, Proc. Natl. Acad. Sci. U.S.A., 104, 20523, 10.1073/pnas.0708800104 McDermott, 2007, Identification of Genotype-Correlated Sensitivity to Selective Kinase Inhibitors by Using High-Throughput Tumor Cell Line Profiling, Proc. Natl. Acad. Sci. U.S.A., 104, 19936, 10.1073/pnas.0707498104 Davis, 2011, Comprehensive Analysis of Kinase Inhibitor Selectivity, Nat. Biotechnol., 29, 1046, 10.1038/nbt.1990 Metz, 2011, Navigating the Kinome, Nat. Chem. Biol., 7, 200, 10.1038/nchembio.530 Anastassiadis, 2011, Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity, Nat. Biotechnol., 29, 1039, 10.1038/nbt.2017 Kitagawa, 2013, Activity-Based Kinase Profiling of Approved Tyrosine Kinase Inhibitors, Genes Cells, 18, 110, 10.1111/gtc.12022 Tang, 2014, Making Sense of Large-Scale Kinase Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis, J. Chem. Inf. Model., 54, 735, 10.1021/ci400709d Uitdehaag, 2014, Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use, PLoS One, 9, 10.1371/journal.pone.0092146 Huber, 2014, Stereospecific Targeting of MTH1 by (S)-Crizotinib as an Anticancer Strategy, Nature, 508, 222, 10.1038/nature13194 Christmann-Franck, 2016, Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way Toward Selective Promiscuity by Design?, J. Chem. Inf. Model., 56, 1654, 10.1021/acs.jcim.6b00122 Duong-Ly, 2016, Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases, Cell Rep., 14, 772, 10.1016/j.celrep.2015.12.080 Uitdehaag, 2016, Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors, Mol. Cancer Ther., 15, 3097, 10.1158/1535-7163.MCT-16-0403 Willemsen-Seegers, 2017, Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied With Surface Plasmon Resonance, J. Mol. Biol., 429, 574, 10.1016/j.jmb.2016.12.019 Chiu, 2013, KIDFamMap: A Database of Kinase-Inhibitor-Disease Family Maps for Kinase Inhibitor Selectivity and Binding Mechanisms, Nucleic Acids Res., 41, D430, 10.1093/nar/gks1218 Ortutay, 2005, KinMutBase: A Registry of Disease-Causing Mutations in Protein Kinase Domains, Hum. Mutat., 25, 435, 10.1002/humu.20166 Richardson, 2009, MoKCa Database—Mutations of Kinases in Cancer, Nucleic Acids Res., 37, D824, 10.1093/nar/gkn832 Jadeau, 2012, BYKdb: The Bacterial Protein tYrosine Kinase Database, Nucleic Acids Res., 40, D321, 10.1093/nar/gkr915 Wang, 2014, EKPD: A Hierarchical Database of Eukaryotic Protein Kinases and Protein Phosphatases, Nucleic Acids Res., 42, D496, 10.1093/nar/gkt1121 Krupa, 2004, KinG: A Database of Protein Kinases in Genomes, Nucleic Acids Res., 32, D153, 10.1093/nar/gkh019 Milanesi, 2005, Systematic Analysis of Human Kinase Genes: A Large Number of Genes and Alternative Splicing Events Result in Functional and Structural Diversity, BMC Bioinformatics, 6, S20, 10.1186/1471-2105-6-S4-S20 Cicenas, 2013, Welcome to the Incredible World of MAP Kinases, MAP Kinase, 2, 1, 10.4081/mk.2013.e1 Mcskimming, 2015, ProKinO: A Unified Resource for Mining the Cancer Kinome, Hum. Mutat., 36, 175, 10.1002/humu.22726 Dardick, 2007, The Rice Kinase Database. A Phylogenomic Database for the Rice Kinome, Plant Physiol., 143, 579, 10.1104/pp.106.087270 Van Linden, 2014, KLIFS: A Knowledge-Based Structural Database to Navigate Kinase-Ligand Interaction Space, J. Med. Chem., 57, 249, 10.1021/jm400378w Kim, 2013, K-Map: Connecting Kinases With Therapeutics for Drug Repurposing and Development, Hum. Genomics, 7, 20, 10.1186/1479-7364-7-20 Ryall, 2015, Identifying Kinase Dependency in Cancer Cells by Integrating High-Throughput Drug Screening and Kinase Inhibition Data, Bioinformatics, 31, 3799, 10.1093/bioinformatics/btv427 Goldberg, 2013, Kinannote, a Computer Program to Identify and Classify Members of the Eukaryotic Protein Kinase Superfamily, Bioinformatics, 29, 2387, 10.1093/bioinformatics/btt419 McSkimming, 2017, Classifying Kinase Conformations Using a Machine Learning Approach, BMC Bioinformatics, 18, 86, 10.1186/s12859-017-1506-2 Koscielny, 2017, Open Targets: A Platform for Therapeutic Target Identification and Validation, Nucleic Acids Res., 45, D985, 10.1093/nar/gkw1055 Chartier, 2013, Kinome Render: A Stand-Alone and Web-Accessible Tool to Annotate the Human Protein Kinome Tree, PeerJ, 1, 10.7717/peerj.126 Martin, 2009, Kinomer v. 1.0: A Database of Systematically Classified Eukaryotic Protein Kinases, Nucleic Acids Res., 37, D244, 10.1093/nar/gkn834 Scheeff, 2010, Genomics, Evolution, and Crystal Structure of a New Family of Bacterial Spore Kinases, Proteins Struct. Funct. Bioinf., 78, 1470, 10.1002/prot.22663 Kanev, 2017, Structural Chemogenomics Databases to Navigate Protein–Ligand Interaction Space, Vol. 1, 444 Sharma, 2016, High Quality, Small Molecule-Activity Datasets for Kinase Research, F1000Res., 5, 1366, 10.12688/f1000research.8950.3 Drewry, 2014, Seeding Collaborations to Advance Kinase Science With the GSK Published Kinase Inhibitor Set (PKIS), Curr. Top. Med. Chem., 14, 340, 10.2174/1568026613666131127160819 Elkins, 2015, Comprehensive Characterization of the Published Kinase Inhibitor Set, Nat. Biotechnol., 34, 95, 10.1038/nbt.3374 Dranchak, 2013, Profile of the GSK Published Protein Kinase Inhibitor Set Across ATP-Dependent and -Independent Luciferases: Implications for Reporter-Gene Assays, PLoS One, 8, 10.1371/journal.pone.0057888 Hu, 2015, Current Compound Coverage of the Kinome, J. Med. Chem., 58, 30, 10.1021/jm5008159 Chen, 2010, SiMMap: A Web Server for Inferring Site-Moiety Map to Recognize Interaction Preferences Between Protein Pockets and Compound Moieties, Nucleic Acids Res., 38, W424, 10.1093/nar/gkq480 Baeissa, 2016, Mutational Patterns in Oncogenes and Tumour Suppressors, Biochem. Soc. Trans., 44, 925, 10.1042/BST20160001 Kaminker, 2007, CanPredict: A Computational Tool for Predicting Cancer-Associated Missense Mutations, Nucleic Acids Res., 35, W595, 10.1093/nar/gkm405 The UniProt Consortium, 2017, UniProt: The Universal Protein Knowledgebase, Nucleic Acids Res., 45, D158, 10.1093/nar/gkw1099 Fabregat, 2016, The Reactome Pathway Knowledgebase, Nucleic Acids Res., 44, D481, 10.1093/nar/gkv1351 Kannan, 2005, Did Protein Kinase Regulatory Mechanisms Evolve Through Elaboration of a Simple Structural Component?, J. Mol. Biol., 351, 956, 10.1016/j.jmb.2005.06.057 Meslamani, 2011, Sc-PDB: A Database for Identifying Variations and Multiplicity of “Druggable” Binding Sites in Proteins, Bioinformatics, 27, 1324, 10.1093/bioinformatics/btr120 McGuire, 2017, 3D-E-Chem-VM: Structural Cheminformatics Research Infrastructure in a Freely Available Virtual Machine, J. Chem. Inf. Model., 57, 115, 10.1021/acs.jcim.6b00686 Berthold, 2007, KNIME: The Konstanz Information Miner, 319 Vieth, 2004, Kinomics—Structural Biology and Chemogenomics of Kinase Inhibitors and Targets, Biochim. Biophys. Acta—Proteins Proteomics, 1697, 243, 10.1016/j.bbapap.2003.11.028 De Moliner, 2003, Inhibition of Protein Kinase CK2 by Anthraquinone-Related Compounds. A Structural Insight, J. Biol. Chem., 278, 1831, 10.1074/jbc.M209367200 Bietz, 2016, SIENA: Efficient Compilation of Selective Protein Binding Site Ensembles, J. Chem. Inf. Model., 56, 248, 10.1021/acs.jcim.5b00588 Sotriffer, 2009, Virtual Screening: Principles, Challenges, and Practical Guidelines, Curr. Opin. Drug Discov. Devel., 12, 519 Volkamer, 2014, Exploiting Structural Information for Drug-Target Assessment, Futur. Med. Chem., 6, 319, 10.4155/fmc.14.3 Villoutreix, 2013, One Hundred Thousand Mouse Clicks Down the Road: Selected Online Resources Supporting Drug Discovery Collected Over a Decade, Drug Discov. Today, 18, 1081, 10.1016/j.drudis.2013.06.013 Liu, 2011, Comparative Modeling: The State of the Art and Protein Drug Target Structure Prediction, Comb. Chem. High Throughput Screen., 14, 532, 10.2174/138620711795767811 Gore, 2012, Implementing an X-Ray Validation Pipeline for the Protein Data Bank, Acta Crystallogr. Sect. D Biol. Crystallogr., 68, 478, 10.1107/S0907444911050359 Stierand, 2007, From Modeling to Medicinal Chemistry: Automatic Generation of Two-Dimensional Complex Diagrams, ChemMedChem, 2, 853, 10.1002/cmdc.200700010 Volkamer, 2010, Analyzing the Topology of Active Sites: On the Prediction of Pockets and Subpockets, J. Chem. Inf. Model., 50, 2041, 10.1021/ci100241y Volkamer, 2012, Combining Global and Local Measures for Structure-Based Druggability Predictions, J. Chem. Inf. Model., 52, 360, 10.1021/ci200454v Henrich, 2010, Computational Approaches to Identifying and Characterizing Protein Binding Sites for Ligand Design, J. Mol. Recognit., 23, 209 Le Guilloux, 2009, Fpocket: An Open Source Platform for Ligand Pocket Detection, BMC Bioinformatics, 10, 168, 10.1186/1471-2105-10-168 Halgren, 2009, Identifying and Characterizing Binding Sites and Assessing Druggability, J. Chem. Inf. Model., 49, 377, 10.1021/ci800324m Desaphy, 2012, Comparison and Druggability Prediction of Protein-Ligand Binding Sites From Pharmacophore-Annotated Cavity Shapes, J. Chem. Inf. Model., 52, 2287, 10.1021/ci300184x Kokh, 2013, TRAPP: A Tool for Analysis of Transient Binding Pockets in Proteins, J. Chem. Inf. Model., 53, 1235, 10.1021/ci4000294 Stank, 2017, TRAPP Webserver: Predicting Protein Binding Site Flexibility and Detecting Transient Binding Pockets, Nucleic Acids Res., W1, W325, 10.1093/nar/gkx277 Egner, 2008, A Structural Biology View of Target Drugability, Expert Opin. Drug Discov., 3, 391, 10.1517/17460441.3.4.391 Schmidtke, 2010, Understanding and Predicting Druggability. A High-Throughput Method for Detection of Drug Binding Sites, J. Med. Chem., 53, 5858, 10.1021/jm100574m Krasowski, 2011, DrugPred: A Structure-Based Approach to Predict Protein Druggability Developed Using an Extensive Nonredundant Data Set, J. Chem. Inf. Model., 51, 2829, 10.1021/ci200266d Sheridan, 2010, Drug-Like Density: A Method of Quantifying The “Bindability” of a Protein Target Based on a Very Large Set of Pockets and Drug-Like Ligands From the Protein Data Bank, J. Chem. Inf. Model., 50, 2029, 10.1021/ci100312t Hajduk, 2005, Druggability Indices for Protein Targets Derived From NMr-Based Screening Data, J. Med. Chem., 48, 2518, 10.1021/jm049131r Komander, 2004, Interactions of LY333531 and Other Bisindolyl Maleimide Inhibitors With PDK1, Structure, 12, 215, 10.1016/j.str.2004.01.005 Hindie, 2009, Structure and Allosteric Effects of Low-Molecular-Weight Activators on the Protein Kinase PDK1, Nat. Chem. Biol, 5, 758, 10.1038/nchembio.208 Rettenmaier, 2015, Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 From Structure-Based Docking, J. Med. Chem., 58, 8285, 10.1021/acs.jmedchem.5b01216 Vass, 2016, Molecular Interaction Fingerprint Approaches for GPCR Drug Discovery, Curr. Opin. Pharmacol., 30, 59, 10.1016/j.coph.2016.07.007 Marcou, 2007, Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints, J. Chem. Inf. Model., 47, 195, 10.1021/ci600342e Jansen, 2016, PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database as a Tool for Structure-Based Drug Design, J. Med. Chem., 59, 7029, 10.1021/acs.jmedchem.5b01813 Desaphy, 2013, Encoding Protein-Ligand Interaction Patterns in Fingerprints and Graphs, J. Chem. Inf. Model., 53, 623, 10.1021/ci300566n Chupakhin, 2013, Predicting Ligand Binding Modes From Neural Networks Trained on Protein-Ligand Interaction Fingerprints, J. Chem. Inf. Model., 53, 763, 10.1021/ci300200r Illergård, 2009, Structure Is Three to Ten Times More Conserved Than Sequence—A Study of Structural Response in Protein Cores, Proteins Struct. Funct. Bioinf., 77, 499, 10.1002/prot.22458 Kellenberger, 2008, How to Measure the Similarity Between Protein Ligand-Binding Sites?, Curr. Comput.—Aided Drug Des., 4, 209, 10.2174/157340908785747401 Nisius, 2012, Structure-Based Computational Analysis of Protein Binding Sites for Function and Druggability Prediction, J. Biotechnol., 159, 123, 10.1016/j.jbiotec.2011.12.005 Kuhn, 2006, From the Similarity Analysis of Protein Cavities to the Functional Classification of Protein Families Using Cavbase, J. Mol. Biol., 359, 1023, 10.1016/j.jmb.2006.04.024 Konc, 2010, ProBiS Algorithm for Detection of Structurally Similar Protein Binding Sites by Local Structural Alignment, Bioinformatics, 26, 1160, 10.1093/bioinformatics/btq100 Baroni, 2007, A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands and Proteins (FLAP): Theory and Application, J. Chem. Inf. Model., 47, 279, 10.1021/ci600253e Schalon, 2008, A Simple and Fuzzy Method to Align and Compare Druggable Ligand-Binding Sites, Proteins Struct. Funct. Genet., 71, 1755, 10.1002/prot.21858 Weill, 2010, Alignment-Free Ultra-High-Throughput Comparison of Druggable Protein-Ligand Binding Sites, J. Chem. Inf. Model., 50, 123, 10.1021/ci900349y Aung, 2008, BSAlign: A Rapid Graph-Based Algorithm for Detecting Ligand-Binding Sites in Protein Structures, Genome Inform., 21, 65 Von Behren, 2013, Fast Protein Binding Site Comparison via an Index-Based Screening Technology, J. Chem. Inf. Model., 53, 411, 10.1021/ci300469h Krieger Roskoski, 2014, The ErbB/HER Family of Protein-Tyrosine Kinases and Cancer, Pharmacol. Res., 79, 34, 10.1016/j.phrs.2013.11.002 Goodford, 1985, A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules, J. Med. Chem., 28, 849, 10.1021/jm00145a002 Cross, 2010, FLAP: GRID Molecular Interaction Fields in Virtual Screening. Validation Using the DUD Data Set, J. Chem. Inf. Model., 50, 1442, 10.1021/ci100221g Ferrario, 2014, BioGPS Descriptors for Rational Engineering of Enzyme Promiscuity and Structure Based Bioinformatic Analysis, PLoS One, 9, 10.1371/journal.pone.0109354 Cortés-Ciriano, 2015, Polypharmacology Modelling Using Proteochemometrics (PCM): Recent Methodological Developments, Applications to Target Families, and Future Prospects, MedChemComm, 6, 24, 10.1039/C4MD00216D Subramanian, 2013, Visually Interpretable Models of Kinase Selectivity Related Features Derived From Field-Based Proteochemometrics, J. Chem. Inf. Model., 53, 3021, 10.1021/ci400369z Volkamer, 2016, Identification and Visualization of Kinase-Specific Subpockets, J. Chem. Inf. Model., 56, 335, 10.1021/acs.jcim.5b00627 Burch, 2014, Property- and Structure-Guided Discovery of a Tetrahydroindazole Series of Interleukin-2 Inducible T-Cell Kinase Inhibitors, J. Med. Chem., 57, 5714, 10.1021/jm500550e Goldstein, 2008, High-Throughput Kinase Profiling as a Platform for Drug Discovery, Nat. Rev. Drug Discov., 7, 391, 10.1038/nrd2541 Merget, 2017, Profiling Prediction of Kinase Inhibitors: Toward the Virtual Assay, J. Med. Chem., 60, 474, 10.1021/acs.jmedchem.6b01611 Ruddigkeit, 2012, Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17, J. Chem. Inf. Model., 52, 2864, 10.1021/ci300415d Ripphausen, 2011, State-of-the-Art in Ligand-Based Virtual Screening, Drug Discov. Today, 16, 372, 10.1016/j.drudis.2011.02.011 Schneider, 2010, Virtual Screening: An Endless Staircase?, Nat. Rev. Drug Discov., 9, 273, 10.1038/nrd3139 Keiser, 2007, Relating Protein Pharmacology by Ligand Chemistry, Nat. Biotechnol., 25, 197, 10.1038/nbt1284 Keiser, 2009, Predicting New Molecular Targets for Known Drugs, Nature, 462, 175, 10.1038/nature08506 Czodrowski, 2016, OCEAN: Optimized Cross rEActivity estimatioN, J. Chem. Inf. Model., 56, 2013, 10.1021/acs.jcim.6b00067 Ferrè, 2014, Computational Methods for Analysis and Inference of Kinase/Inhibitor Relationships, Front. Genet., 5, 196 Martin, 2011, Profile-QSAR: A Novel Meta-QSAR Method That Combines Activities Across the Kinase Family to Accurately Predict Affinity, Selectivity, and Cellular Activity, J. Chem. Inf. Model., 51, 1942, 10.1021/ci1005004 Manallack, 2002, Selecting Screening Candidates for Kinase and G Protein-Coupled Receptor Targets Using Neural Networks, J. Chem. Inf. Comput. Sci., 42, 1256, 10.1021/ci020267c Unterthiner, 2014, Deep Learning as an Opportunity in Virtual Screening, 1 Schürer, 2013, Kinome-Wide Activity Modeling From Diverse Public High-Quality Data Sets, J. Chem. Inf. Model., 53, 27, 10.1021/ci300403k Chen, 2012, Comparison of Random Forest and Pipeline Pilot Naïve Bayes in Prospective QSAR Predictions, J. Chem. Inf. Model., 52, 792, 10.1021/ci200615h Xia, 2004, Classification of Kinase Inhibitors Using a Bayesian Model, J. Med. Chem., 47, 4463, 10.1021/jm0303195 Yabuuchi, 2011, Analysis of Multiple Compound—Protein Interactions Reveals Novel Bioactive Molecules, Mol. Syst. Biol., 7, 1 Muzzioli, 2011, Assessing Protein Kinase Selectivity With Molecular Dynamics and MM-PBSA Binding Free Energy Calculations, Chem. Biol. Drug Des., 78, 252, 10.1111/j.1747-0285.2011.01140.x Shukla, 2014, Activation Pathway of Src Kinase Reveals Intermediate States as Targets for Drug Design, Nat. Commun., 5, 3397, 10.1038/ncomms4397 Copeland, 2016, The Drug-Target Residence Time Model: A 10-Year Retrospective, Nat. Rev. Drug Discov., 15, 87, 10.1038/nrd.2015.18 Lu, 2009, Slow-Onset Inhibition of the FabI Enoyl Reductase From Francisella tularensis: Residence Time and in vivo Activity, ACS Chem. Biol., 4, 221, 10.1021/cb800306y Uitdehaag, 2017, Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors With Potent Anti-Proliferative Activity, J. Mol. Biol., 429, 2211, 10.1016/j.jmb.2017.05.014